West Pharmaceutical Services, Inc. earnings per share and revenue
On Feb 12, 2026, WST reported earnings of 2.04 USD per share (EPS) for Q4 25, beating the estimate of 1.85 USD, resulting in a 10.23% surprise. Revenue reached 805.00 million, compared to an expected 802.32 million, with a 0.33% difference. The market reacted with a -1.04% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 12 analysts forecast an EPS of 1.69 USD, with revenue projected to reach 786.62 million USD, implying an decrease of -17.16% EPS, and decrease of -2.28% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
The Cooper Companies, Inc. Common Stock
Report Date
Mar 05, 2026 For Q1 26
Estimate
$1.04
Actual
$1.10
Surprise
+5.74%
Henry Schein Inc
Report Date
Feb 24, 2026 For Q4 25
Estimate
$1.32
Actual
$1.34
Surprise
+1.06%
Merit Medical Systems Inc
Report Date
Feb 24, 2026 For Q4 25
Estimate
$0.97
Actual
$1.04
Surprise
+6.86%
DENTSPLY SIRONA Inc.
Report Date
Feb 26, 2026 For Q4 25
Estimate
$0.28
Actual
$0.27
Surprise
-4.80%
Staar Surgical Co
Report Date
Mar 03, 2026 For Q4 25
Estimate
$0.05
Actual
$0.04
Surprise
-31.39%
FAQ
What were West Pharmaceutical Services, Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, West Pharmaceutical Services, Inc. reported EPS of $2.04, beating estimates by 10.23%, and revenue of $805.00M, 0.33% above expectations.
How did the market react to West Pharmaceutical Services, Inc.'s Q4 2025 earnings?
The stock price moved down -1.04%, changed from $246.16 before the earnings release to $243.61 the day after.
When is West Pharmaceutical Services, Inc. expected to report next?
The next earning report is scheduled for Apr 22, 2026.
What are the forecasts for West Pharmaceutical Services, Inc.'s next earnings report?
Based on 12
analysts, West Pharmaceutical Services, Inc. is expected to report EPS of $1.69 and revenue of $786.62M for Q1 2026.